High-grade atrioventricular block
Conditions
Interventions
Health Volunteer Group :None
RVSP Group:Implantation of a right ventricular septal pacemaker
LBBP Group:Implantation of a left bundle branch pacemaker
Lot-CRT Group:Implant left bundle branch to optimize CRT
BiV-CRT group:Implantation of traditional dual-chamber pacemaker CRT
Sponsors
Guizhou Provincial People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Trial One: (1) All biochemical indicators from the physical examination are within the normal range, and the results of the electrocardiogram and imaging examinations are normal; (2) No history of chronic diseases such as hypertension, diabetes, pulmonary heart disease, or renal insufficiency; (3) No history of long-term medication use; (4) The patient and the patient's family have signed the informed consent form and have agreed to participate in this study. 2. Trial Two: (1) Electrocardiogram indicates patients with high-degree or third-degree AV block (III°AVB); (2) Age >= 18 years; (3) LVEF: males >= 52%, females >= 54%; (4) No past or current clinical manifestations of heart failure; (5) First-time implantation of a pacemaker; (6) Pacemaker follow-up programming indicates ventricular pacing dependence (pacing percentage >40%); (7) The patient and the patient's family have signed the informed consent form and agreed to participate in this study. 3. Trial Three: (1) Meets the Class I, IIa, or IIb indications for CRT implantation according to the 2013 EHRA/ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy; (2) After 3 to 6 months of treatment with scientifically optimized maximum tolerated doses of heart failure medications such as ACE inhibitors/ARBs, diuretics, aldosterone receptor antagonists, beta-blockers, sacubitril/valsartan, and ivabradine, heart failure symptoms still recur; (3) The patient and the patient's family are fully informed, voluntarily agree to participate in this study, and have signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Trial 1: (1) Male LVEF =45mm; (6) Cirrhosis, bilirubin elevated 2-fold, or AST/ALT/ALP elevated 3-fold; (7) Long-term dialysis, kidney transplantation, or chronic kidney disease with serum creatinine >200 µmol/L; (8) Poor ultrasound image quality due to obesity, being underweight, hyperinflated lungs, or other reasons; 3. Trial 3: (1) Combined long-term dialysis, kidney transplantation, or chronic kidney disease with serum creatinine >200 µmol/L; (2) Combined cirrhosis, bilirubin elevated 2-fold, or AST/ALT/ALP elevated 3-fold; (3) Combined severe pulmonary heart disease with right ventricular basal diameter >=45mm; (4) Combined psychiatric disorders and severe neurological diseases; (5) Combined malignant tumors; (6) Contraindications for CRT/CRT-D therapy; (7) Poor ultrasound image quality due to obesity, being underweight, hyperinflated lungs, or other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Echocardiography image;6 minute walking distance test, 6-MWT;Peak strain dispersion, PSD;Left ventricular global longitudinal strain ,GLS;Left ventricular global work index,GWI;Global constructive work,GCW;Global waste work,GWW;Global work efficiency,GWE;left ventricular ejection fraction ,LVEF;Left ventricular end-diastolic diameter,LVEDD;Left atrium diameter,LAd; | — |
Secondary
| Measure | Time frame |
|---|---|
| Width of the QRS wave in electrocardiogram ; | — |
Countries
China
Contacts
Public ContactTan Jing
Guizhou Provincial People's Hospital
Outcome results
None listed